Kent E. Wallner
#159,271
Most Influential Person Now
Kent E. Wallner's AcademicInfluence.com Rankings
Kent E. Wallnerphilosophy Degrees
Philosophy
#9129
World Rank
#12639
Historical Rank
Logic
#6121
World Rank
#7604
Historical Rank
Kent E. Wallnerbiology Degrees
Biology
#12478
World Rank
#15956
Historical Rank
Neuroscience
#2097
World Rank
#2155
Historical Rank
Download Badge
Philosophy Biology
Kent E. Wallner's Degrees
- Doctorate Medicine University of California, San Francisco
- PhD Neuroscience University of California, San Francisco
Why Is Kent E. Wallner Influential?
(Suggest an Edit or Addition)Kent E. Wallner's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. (1989) (752)
- The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. (1991) (448)
- Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. (1996) (333)
- Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. (1995) (292)
- Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting (2009) (278)
- Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. (1995) (269)
- Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. (2000) (266)
- Comparison of the 5-Year Outcome and Morbidity of Three-Dimensional Conformal Radiotherapy Versus Transperineal Permanent Iodine-125 Implantation for Early-Stage Prostatic Cancer (1999) (216)
- Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. (1986) (157)
- Treatment results of juvenile pilocytic astrocytoma. (1988) (154)
- 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. (1996) (152)
- Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. (2010) (151)
- Erectile function after prostate brachytherapy. (2005) (142)
- Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. (2006) (138)
- Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective study. (2002) (130)
- Treatment-related symptoms during the first year following transperineal 125I prostate implantation. (1994) (129)
- Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. (2003) (122)
- A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction. (2001) (121)
- Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. (1997) (118)
- Long-term urinary quality of life after permanent prostate brachytherapy. (2003) (118)
- 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial. (2003) (116)
- A CT-based evaluation method for permanent implants: application to prostate. (1993) (114)
- The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction. (2002) (111)
- Prostate brachytherapy seed identification on post-implant TRUS images. (2003) (105)
- Treatment of oligodendrogliomas with or without postoperative irradiation. (1988) (105)
- Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. (2005) (100)
- The morbidity of transperineal template‐guided prostate mapping biopsy (2008) (99)
- Short-term freedom from disease progression after I-125 prostate implantation. (1994) (98)
- CT-based dosimetry for transperineal I-125 prostate brachytherapy. (1997) (96)
- Effect of cisplatin resistance on cellular radiation response. (1987) (95)
- Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. (2002) (95)
- Efficacy of irradiation for incompletely excised acoustic neurilemomas. (1987) (93)
- Prostate-specific antigen spikes after permanent prostate brachytherapy. (2002) (92)
- Good performance status of long-term disease-free survivors of intracranial gliomas. (1993) (92)
- Intracranial ependymomas: results of treatment with partial or whole brain irradiation without spinal irradiation. (1986) (91)
- Short‐term sexual function after prostate brachytherapy (2001) (91)
- Postradiotherapy surveillance practice for head and neck squamous cell carcinoma—too much for too little? (2003) (89)
- Hyperthermic enhancement of cell killing by mitomycin C in mitomycin C-resistant Chinese hamster ovary cells. (1987) (89)
- The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors. (1991) (88)
- Clinical course of rectal bleeding following I-125 prostate brachytherapy. (1998) (88)
- A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapy. (2007) (87)
- Comparability of CT-based and TRUS-based prostate volumes. (1999) (84)
- Risk factors for the development of prostate brachytherapy related urethral strictures. (2006) (82)
- Ultrasonography and fluoroscopic fusion for prostate brachytherapy dosimetry. (2002) (82)
- Rectal fistulas after prostate brachytherapy. (2005) (81)
- An improved method for computerized tomography-planned transperineal 125iodine prostate implants. (1991) (81)
- 1–125 Versus Pd‐103 for Low‐Risk Prostate Cancer: Morbidity Outcomes from a Prospective Randomized Multicenter Trial (2002) (80)
- Brachytherapy radiation doses to the neurovascular bundles. (2000) (74)
- Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. (2005) (72)
- Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy. (2010) (70)
- Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. (2006) (70)
- Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. (2005) (70)
- Reviving the acid phosphatase test for prostate cancer. (2007) (69)
- Minimizing prostate brachytherapy-related morbidity. (2003) (69)
- Effect of drug exposure duration and sequencing on hyperthermic potentiation of mitomycin-C and cisplatin. (1987) (64)
- American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy. (2002) (63)
- Patterns of second recurrence of malignant astrocytomas. (1990) (63)
- Short-term morbidity from CT-planned transperineal I-125 prostate implants. (1993) (63)
- CT-based optimized planning for transperineal prostate implant with customized template. (1991) (61)
- I‐125 Versus Pd‐103 for Low‐Risk Prostate Cancer: Long‐Term Morbidity Outcomes From a Prospective Randomized Multicenter Controlled Trial (2005) (61)
- Penile bulb imaging. (2002) (61)
- Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. (2007) (59)
- Primary causes of death after permanent prostate brachytherapy. (2008) (58)
- Quantifying the effect of dose inhomogeneity in brachytherapy: application to permanent prostatic implant with 125I seeds. (1994) (58)
- Long‐term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high‐risk features (2007) (58)
- Treatment of Metastatic Chemodectoma (1992) (57)
- Management of sexual dysfunction after prostate brachytherapy. (2003) (57)
- Extracapsular Radiation Dose Distribution After Permanent Prostate Brachytherapy (2003) (57)
- Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy (2006) (56)
- Dysuria after permanent prostate brachytherapy. (2003) (55)
- Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer. (1995) (54)
- Long‐term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma (2003) (54)
- The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. (2006) (54)
- Semiautomatic 3-D Prostate Segmentation from TRUS Images Using Spherical Harmonics (2006) (54)
- Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. (2004) (53)
- Erectile function durability following permanent prostate brachytherapy. (2009) (52)
- Adriamycin resistance, heat resistance and radiation response in Chinese hamster fibroblasts. (1986) (52)
- Prostate brachytherapy seed migration to the right coronary artery associated with an acute myocardial infarction. (2006) (51)
- Dosimetric and radiographic correlates to prostate brachytherapy‐related rectal complications (2001) (51)
- Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam. (2007) (51)
- 125iodine reimplantation for locally progressive prostatic carcinoma. (1990) (50)
- Fluoroscopic visualization of the prostatic urethra to guide transperineal prostate implantation. (1994) (50)
- The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials. (2003) (50)
- Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma. (1999) (49)
- Urinary incontinence in patients who have a TURP/TUIP following prostate brachytherapy (1998) (48)
- Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. (1999) (46)
- Long-term urinary function after transperineal brachytherapy for patients with large prostate glands. (2001) (44)
- Electromagnetic tracking of intrafraction prostate displacement in patients externally immobilized in the prone position. (2009) (44)
- Use of pelvic CT scanning to evaluate pubic arch interference of transperineal prostate brachytherapy. (1999) (43)
- Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis. (2005) (42)
- Iodine 125 brachytherapy for early stage prostate cancer: new techniques may achieve better results. (1991) (42)
- Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. (2005) (41)
- Clinical correlates to PSA spikes and positive repeat biopsies after prostate brachytherapy. (2003) (40)
- Patient reported complications after prostate brachytherapy. (2001) (40)
- Treatment Margins Predict Biochemical Outcomes After Prostate Brachytherapy (2004) (39)
- Extracapsular radiation dose distribution following permanent prostate brachytherapy (2001) (39)
- Radiation safety parameters following prostate brachytherapy. (1999) (39)
- Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. (2006) (39)
- Brachytherapy in men aged ≤ 54 years with clinically localized prostate cancer (2006) (38)
- Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy. (2004) (38)
- Late rectal function after prostate brachytherapy. (2003) (37)
- Effect of transurethral resection on urinary quality of life after permanent prostate brachytherapy. (2004) (36)
- Prostate brachytherapy in patients with inflammatory bowel disease. (1998) (36)
- Transperineal brachytherapy in patients with large prostate glands (2000) (36)
- Inability of computed tomography appearance of recurrent malignant astrocytoma to predict survival following reoperation. (1989) (36)
- Use of TRUS to predict pubic arch interference of prostate brachytherapy. (1999) (35)
- 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial. (2005) (35)
- The effect of interobserver differences in post-implant prostate CT image interpretation on dosimetric parameters. (2003) (35)
- Argon plasma coagulation for rectal bleeding after prostate brachytherapy. (2001) (35)
- Treatment of brain metastases from bladder cancer. (1993) (33)
- Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity. (2002) (33)
- Isotope and patient age predict for PSA spikes after permanent prostate brachytherapy. (2007) (33)
- Late urinary function after prostate brachytherapy. (2002) (32)
- Intraoperative ultrasound-fluoroscopy fusion can enhance prostate brachytherapy quality. (2007) (32)
- Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy. (2003) (32)
- Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Beam Irradiation and Brachytherapy (2010) (32)
- Whole-pelvis radiotherapy in combination with interstitial brachytherapy: does coverage of the pelvic lymph nodes improve treatment outcome in high-risk prostate cancer? (2009) (30)
- Radiation therapy for the treatment of non-eight nerve intracranial neurilemmoma. (1988) (30)
- Anticipating prostatic volume changes due to prostate brachytherapy. (1999) (30)
- Radiographic findings and morbidity in patients treated with stereotactic radiosurgery. (1998) (30)
- Time-dependent changes in CT-based dosimetry of I-125 prostate brachytherapy. (1998) (29)
- Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy. (2006) (28)
- Effect of post-implant edema on prostate brachytherapy treatment margins. (2005) (28)
- Temporary PSA rises and repeat prostate biopsies after brachytherapy. (2001) (27)
- Reversal of cranial nerve dysfunction with radiation therapy in adults with lymphoma and leukemia. (1990) (27)
- Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation. (2007) (27)
- Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancer. (2004) (26)
- Perirectal seeds as a risk factor for prostate brachytherapy-related rectal bleeding. (2004) (26)
- Treatment margins for prostate brachytherapy. (2000) (25)
- Brachytherapy‐related dysuria (2005) (25)
- Seed-based transrectal ultrasound-fluoroscopy registration method for intraoperative dosimetry analysis of prostate brachytherapy. (2008) (25)
- High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapy. (2011) (25)
- Rectal function following brachytherapy with or without supplemental external beam radiation: results of two prospective randomized trials. (2003) (24)
- Prostate cancer death is unlikely in high‐risk patients following quality permanent interstitial brachytherapy (2011) (24)
- Long-Term Rectal Function After Permanent Prostate Brachytherapy (2007) (24)
- Electromagnetic transponders indicate prostate size increase followed by decrease during the course of external beam radiation therapy. (2011) (24)
- Patient selection for prostate brachytherapy: more myth than fact. (2004) (23)
- Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy. (2008) (23)
- Monotherapeutic brachytherapy for clinically organ-confined prostate cancer. (2005) (23)
- Prostate cryotherapy: more questions than answers. (2005) (23)
- Long-term outcome for very high-risk prostate cancer treated primarily with a triple modality approach to include permanent interstitial brachytherapy. (2012) (22)
- Intraoperative fluoroscopic dose assessment in prostate brachytherapy patients. (2005) (22)
- Prognostic significance of perineural invasion on biochemical progression-free survival after prostate brachytherapy. (2005) (21)
- Interpretation of pre- versus postimplant TRUS images. (2003) (21)
- Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy. (2004) (21)
- Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103Pd? Results of two prospective randomized trials. (2015) (21)
- Severe rectal complications after prostate brachytherapy. (2015) (20)
- Obesity Is Not Predictive of Overall Survival Following Permanent Prostate Brachytherapy (2007) (19)
- Erratum: Good performance status of long-term disease-free survivors of intracranial gliomas (International Journal of Radiation Oncology Biology (1993) 26 (129-133)) (1993) (19)
- A reappraisal of local anesthesia for prostate brachytherapy. (2003) (19)
- Dosimetry of an Extracapsular Anulus Following Permanent Prostate Brachytherapy (2007) (19)
- Clinical course and dosimetry of rectal fistulas after prostate brachytherapy (2001) (19)
- Temporal effect of neoadjuvant androgen deprivation therapy on PSA kinetics following permanent prostate brachytherapy with or without supplemental external beam radiation. (2004) (19)
- Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension. (2007) (18)
- Squamous cell carcinoma of the head and neck after radiation therapy for Hodgkin's disease a report of two cases and a review of the literature (1985) (18)
- Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB. (2009) (18)
- Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma. (2007) (18)
- Prostate brachytherapy under local anesthesia; lessons from the first 600 patients. (2002) (18)
- Prognostic Significance of Percent Positive Biopsies in Clinically Organ Confined Prostate Cancer Treated with Permanent Prostate Brachytherapy With or Without Supplemental External Beam Radiation (2004) (18)
- Permanent prostate brachytherapy: is supplemental external-beam radiation therapy necessary? (2006) (18)
- Retreatment of pediatric brain tumors with radiation and misonidazole: Results of a CCSG/RTOG phase I/II study (1986) (18)
- Permanent prostate brachytherapy in prostate glands <20 cm(3). (2010) (17)
- Corneal macrophage infiltrates following ocular herpes simplex virus type 1 challenge vary in BALB/c mice vaccinated with different vaccines. (2000) (17)
- 20 Gy versus 44 Gy of supplemental external beam radiotherapy with palladium-103 for patients with greater risk disease: results of a prospective randomized trial. (2012) (17)
- Medical malpractice of prostate brachytherapy. (2004) (17)
- Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy. (2008) (16)
- High-dose regions versus likelihood of cure after prostate brachytherapy. (2005) (16)
- Clinical correlates of high intraprostatic brachytherapy dose volumes. (2002) (16)
- American brachytherapy society survey of current clinical practice for permanent brachytherapy of prostate cancer (1997) (16)
- Gross hematuria after prostate brachytherapy. (2003) (16)
- The impact of radiation dose to the urethra on brachytherapy-related dysuria. (2005) (16)
- Local anesthesia for prostate brachytherapy. (1999) (16)
- The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy. (2004) (16)
- Role of trospium chloride in brachytherapy-related detrusor overactivity. (2008) (16)
- Is supplemental external beam radiation therapy essential to maximize brachytherapy outcomes in patients with unfavorable intermediate-risk disease? (2016) (15)
- The Impact of Prostate Volume and Neoadjuvant Androgen‐Deprivation Therapy on Urinary Function Following Prostate Brachytherapy (2004) (15)
- Obesity is not predictive of overall survival following permanent prostate brachytherapy. (2007) (15)
- Long-term outcomes of prostate cancer patients with Gleason pattern 5 treated with combined brachytherapy and external beam radiotherapy. (2013) (15)
- Prostate brachytherapy in obese patients. (2002) (15)
- Serum testosterone kinetics after brachytherapy for clinically localized prostate cancer. (2012) (14)
- Gleason score 7 prostate cancer treated with interstitial brachytherapy with or without supplemental external beam radiation and androgen deprivation therapy: is the primary pattern on needle biopsy prognostic? (2013) (14)
- Determining source strength and source distribution for a transperineal prostate implant (1996) (14)
- Permanent Interstitial Brachytherapy for Clinically Organ-Confined High-Grade Prostate Cancer With a Pretreatment PSA < 20 ng/mL (2004) (14)
- Interstitial brachytherapy should be standard of care for treatment of high-risk prostate cancer. (2008) (14)
- 1011 Palladium-103 brachytherapy for clinical prostate carcinomas (1997) (13)
- Epididymitis after prostate brachytherapy. (2004) (13)
- Biochemical and Functional Outcomes Following Brachytherapy With or Without Supplemental Therapies in Men ≤50 Years of Age With Clinically Organ-Confined Prostate Cancer (2008) (13)
- Follow-up care for cancer: making the benefits equal the cost. (2000) (13)
- Low risk of perioperative infection without prophylactic antibiotics for transperineal prostate brachytherapy. (1996) (13)
- The case for hypofractionation of localized prostate cancer. (2013) (13)
- Selecting patients with pretreatment postvoid residual urine volume less than 100 mL may favorably influence brachytherapy-related urinary morbidity. (2005) (13)
- Tumor control probability for permanent implants in prostate. (1993) (13)
- Radiation treatment planning for malignant astrocytomas (1991) (13)
- Pathologic features from prostate needle biopsy and prognosis after I-125 brachytherapy. (1998) (13)
- Preexisting histologic evidence of prostatitis is unrelated to postimplant urinary morbidity (2001) (13)
- Iodine-125 vs palladium-103 for low-risk prostate cancer: Preliminary urinary functional outcomes from a prospective randomized multicenter trial (2000) (13)
- The Prognostic Significance of Gleason Pattern 5 in Prostate Cancer Patients Treated with Pd 103 plus Beam Radiation Therapy (2004) (13)
- 1056 Conformal brachytherapy boost to external beam irradiation for clinically localized high risk prostate cancer (1995) (13)
- Patient perception of local anesthesia for prostate brachytherapy. (2000) (12)
- Time to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment (2013) (12)
- Influence of hormonal therapy on late rectal function after permanent prostate brachytherapy with or without supplemental external beam radiotherapy. (2004) (12)
- Prostate brachytherapy in men > or =75 years of age. (2008) (12)
- Follow-up costs after external radiation for low risk prostate cancer. (1999) (12)
- There Is a Wide Range of Predictive Dosimetric Factors for I-125 and Pd-103 Prostate Brachytherapy (2008) (12)
- The impact of acute urinary morbidity on late urinary function after permanent prostate brachytherapy. (2007) (12)
- Extraprostatic Seed Placement and Its Effect on Seed Loss (2005) (11)
- Seed-based ultrasound and fluoroscopy registration using iterative optimal assignment for intraoperative prostate brachytherapy dosimetry (2007) (11)
- The Impact of Primary Gleason Grade on Biochemical Outcome Following Brachytherapy for Hormone‐Naive Gleason Score 7 Prostate Cancer (2005) (11)
- Brachytherapy in patients with small prostate glands. (2000) (11)
- The Impact of Diabetes Mellitus on Survival in Men With Clinically Localized Prostate Cancer Treated With Permanent Interstitial Brachytherapy (2010) (11)
- Temporal relationship between prostate brachytherapy and the diagnosis of colorectal cancer. (2006) (11)
- Isodose patterns in patients with inadequate prostate brachytherapy coverage. (2003) (11)
- Urinary morbidity in brachytherapy patients with median lobe hyperplasia. (2002) (10)
- Urinary incontinence in patients who have a TURP/TUIP following prostate brachytherapy. (1999) (10)
- Impact of transurethral resection on the long-term outcome of patients with prostatic carcinoma. (1993) (10)
- Prognostic importance of tobacco use in men receiving definitive prostate brachytherapy. (2012) (10)
- The Incidence of Transition Zone Prostate Cancer Diagnosed by Transperineal Template Guided Mapping Biopsy: Implications for Treatment Planning (2010) (10)
- Patient-reported long-term rectal function after permanent interstitial brachytherapy for clinically localized prostate cancer. (2012) (10)
- Prostate brachytherapy in patients with median lobe hyperplasia (2000) (10)
- Androgen deprivation therapy: a survival benefit or detriment in men with high-risk prostate cancer? (2010) (10)
- Distant metastases following permanent interstitial brachytherapy for patients with clinically localized prostate cancer. (2011) (9)
- Impact of Transurethral Resection on the Long-Term Outcome of Patients with Prostatic Carcinoma (1993) (9)
- Risk factors for the development of prostate brachytherapy related urethral strictures. Commentary (2006) (9)
- Modification of prostate implants based on postimplant treatment margin assessment. (2002) (9)
- Chronic pelvic pain following prostate brachytherapy: a case report. (2004) (9)
- Treatment of prostate cancer in obese patients. (2006) (9)
- 20 Gy Versus 44 Gy Supplemental Beam Radiation with Pd-103 Prostate Brachytherapy: Early Biochemical Outcomes From a Prospective Randomized Multi-Center Trial (2005) (9)
- Radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors (1989) (9)
- Adjuvant brachytherapy for treatment of chest wall sarcomas. (1991) (8)
- A new device to stabilize templates for transperineal I-125 implants. (1991) (7)
- MR imaging for prostate cancer staging: beauty or beast? (2002) (7)
- Clinical Course of Rectal Bleeding Following I-125 Prostate Brachytherapy (1999) (7)
- Greater biopsy core number is associated with improved biochemical control in patients treated with permanent prostate brachytherapy. (2010) (7)
- Factors impacting all-cause mortality in prostate cancer brachytherapy patients with or without androgen deprivation therapy. (2010) (7)
- Variability of prostate brachytherapy preimplant dosimetry: A multi-institutional analysis (2005) (7)
- Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy. (2003) (7)
- The Prognostic Significance of Gleason Pattern 5 in Prostate Cancer Patients Treated With Pd-103 Brachytherapy (2007) (7)
- Disease-free survival after external beam irradiation and palladium-103 brachytherapy boost for high-risk prostatic carcinoma (1997) (7)
- The correlation between annular treatment margins and biochemical failure in prostate brachytherapy patients with optimized intraprostatic dosimetry. (2011) (6)
- Standardization of prostate brachytherapy treatment plans. (2001) (6)
- Enzymatic prostatic acid phosphatase in the clinical staging of patients diagnosed with prostate cancer. (2005) (6)
- Prostate cancer control and survival in Vietnam veterans exposed to Agent Orange. (2008) (6)
- Prognostic importance of small prostate size in men receiving definitive prostate brachytherapy. (2012) (6)
- Does supplemental external beam radiation therapy impact urinary, bowel, and erectile function following permanent prostate brachytherapy?: results of two prospective randomized trials (2017) (6)
- The Time Gap Between Pd-103 Prostate Brachytherapy and Supplemental Beam Radiation Does Not Impact on Rectal Morbidity or Likelihood of Cure (2007) (5)
- Obesity does not correlate with adverse pathologic findings on transperineal template-guided mapping biopsy of the prostate. (2011) (5)
- Relationship between prostate cancer mortality and number of unfavourable risk factors in men treated with definitive brachytherapy (2010) (5)
- Brachytherapy versus brachytherapy plus beam radiation for prostate cancer: morbidity outcomes from two prospective randomized multicenter trials (2002) (5)
- 2103 Rectal and urinary morbidity in patients undergoing prostate I-125 implant (1997) (5)
- Patient reported short-term complications after prostate brachytherapy (2000) (5)
- Rapid strand™ vs. loose (iodine-125 seeds): A prospective randomized trial (2004) (5)
- An analysis of late urinary toxicity based upon urethra dose volume histograms after transperineal permanent interstitial iodine 125 prostate brachytherapy (2000) (4)
- Technologic evolution in the treatment of prostate cancer. Clinical, financial, and legal implications for managed care organizations. (2007) (4)
- Late toxicity of transperineal permanent 125iodine implantation of the prostate for clinically localized prostate cancer (1998) (4)
- Dosimetric Parameters of Rectal Toxicity and Fistula Formation After Prostate Brachytherapy (2007) (4)
- Rectal function following brachytherapy: results of two prospective randomized trials (2003) (4)
- PSA response after transperineal I-125 prostate implantation (1993) (4)
- Comparison of the Effect of Prone versus Supine Patient Immobilization on Intrafraction Prostate Displacement Monitored by Real-time Electromagnetic Tracking (2009) (4)
- Erectile dysfunction is predictive of all‐cause mortality in patients with prostate cancer treated with permanent interstitial brachytherapy (2012) (4)
- Comparison of outcome and morbidity of 3-dimensional conformal radiotherapy versus transperineal permanent I-125 implantation for early stage prostatic cancer (1998) (3)
- Morbidity after brachytherapy for prostate adenocarcinoma. (2004) (3)
- Prostate brachytherapy in patients with prior evidence of prostatitis. (1999) (3)
- Post-treatment surveillance practice following radiotherapy for head and neck squamous cell carcinoma—too much for too little (2001) (3)
- PSA spike after brachytherapy For localized prostate cancer. (2007) (3)
- Factors affecting patient selection for prostate brachytherapy: what nurses should know. (2005) (3)
- Prostate brachytherapy in patients with a penile prosthesis (2001) (3)
- Prostate brachytherapy in patients with median lobe hyperplasia. (2000) (3)
- Patient Selection for Prostate Brachytherapy (2005) (3)
- Prostatic acid phosphatase predicts cancer-specific survival after Palladium-103 brachytherapy for prostate cancer (2007) (3)
- Short-term results of computerized tomographic-based transperineal iodine-125 prostate implantation (1993) (2)
- 304 Brachytherapy for prostate cancer (1996) (2)
- Radiotherapeutic strategies in the management of clinically localized, "low-risk" prostate cancer: selection, results, and the search for answers. (1998) (2)
- Improved outcomes with radiation for prostate cancer. (2001) (2)
- cExternal beam radiation results in minimal changes in post void residual urine volumes during the treatment of clinically localized prostate cancer (2009) (2)
- Benign prostate-specific antigen (PSA) spikes following permanent prostate brachytherapy (2002) (2)
- Erectile function following permanent prostate brachytherapy: Results of two prospective randomized trials (2004) (2)
- Brachytherapy-associated erectile dysfunction (2005) (2)
- Prophylactic versus therapeutic alpha blockers in the management of short term urinary morbidity following permanent prostate brachytherapy (2002) (2)
- Effect of total body irradiation lung block parameters on lung doses using three‐dimensional dosimetry (2022) (2)
- 5 CT-based dosimetry for transperineal I-125 prostate brachytherapy (1996) (2)
- Electromagnetic Tracking of Intrafraction Prostate Displacement among Patients Externally Immobilize (2009) (2)
- Brachytherapy in men ≤54 years of age with clinically localized prostate cancer (2006) (2)
- Biochemical failure rates following combination external beam radiation and Palladium-103 boost for clinically localized high risk prostate cancer: 10 year results (2002) (2)
- The Impact of Needle Trauma on Urinary, Bowel and Erectile Function Following Transperineal Template Guided Prostate Saturation Biopsy: Implications for Brachytherapy (2007) (2)
- Brachytherapy alone for early stage prostate cancer — Part I: Patient selection and technique and brachytherapy for early prostate cancer (1998) (2)
- 45 – Cancer of the Prostate (2010) (2)
- The impact of urinary storm on late urinary function following permanent prostate brachytherapy (2007) (2)
- Commentary on "Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: Implications for prostate brachytherapy". (2013) (2)
- Failure patterns after intravascular brachytherapy for in‐stent coronary restenosis (2022) (2)
- Cystourethroscopic findings before and after prostate brachytherapy. (2000) (2)
- The Stock/Ferrari/Stone Article Reviewed (1998) (1)
- EARLY INFECTIOUS COMPLICATIONS WITH TRANSPONDER PLACEMENT FOR EXTERNAL BEAM RADIATION THERAPY FOR PROSTATE CANCER (2012) (1)
- Intravascular coronary brachytherapy combined with a drug-coated balloon. (2021) (1)
- Long-term Prostate Cancer Control (13 Year Actuarial) in Patients with a High Likelihood of Extracapsular Cancer Extension Using PD-103 Brachytherapy and Supplemental Beam Radiation (2005) (1)
- In response to Dr. Lee (2003) (1)
- Prostate Cancer Death is Unlikely in High-Risk Patients Following High-Quality Brachytherapy (2010) (1)
- In response to Aronowitz et al. (2002) (1)
- Androgen deprivation therapy (2010) (1)
- 2 Patient selection for prostate brachytherapy (2000) (1)
- Urethral stents and prostate brachytherapy (1999) (1)
- Patterns of Death Following Permanent Prostate Brachytherapy (2007) (1)
- Brachytherapy for prostate cancer (1993) (1)
- Effect of Lung Blocks Parameters on Lung and Cardiac Doses in Total Body Irradiation Using 3D Dosimetry. (2021) (1)
- Permanent prostate brachytherapy for high-risk prostate cancer (2007) (1)
- Factors impacting all cause mortality in men receiving androgen deprivation therapy with prostate brachytherapy (2009) (1)
- Impact of lung block shape on cardiac dose for total body irradiation (2022) (1)
- Comparison of MRI pulse sequences in defining prostate volume after permanent implantation: in regard to McLaughlin et al., IJROBP 2002;54:703-711. (2003) (1)
- Prostate brachytherapy treatment planning using a standard plan (2000) (1)
- 316C Brachytherapy alone for early stage prostate cancer — part I: Patient selection and techniques (1997) (1)
- Morbidity after brachytherapy for prostate adenocarcinoma [1] (multiple letters) (2004) (1)
- The impact of primary Gleason grade on biochemical outcome following brachytherapy for Gleason score 7 prostate cancer (2005) (1)
- Androgen Deprivation Therapy in High-Risk Prostate Cancer with Gleason Score 8-10 and PSA ≤ 15 Treated with Permanent Interstitial Brachytherapy (2010) (1)
- Isotope and patient age predict for PSA spikes following permanent prostate brachytherapy (2007) (1)
- Radiation thresholds and rehabilitative therapy with erectile preservation after radiotherapy for prostate cancer (2007) (1)
- Rectal Doses Can Be Safely Minimized Without Affecting the Likelihood of Cure After Prostate Brachytherapy (2005) (1)
- Reversal of cranial nerve dysfunction in lymphoma and leukemia with radiation therapy (1989) (1)
- Relationship between Prostate Cancer Mortality and Number of Unfavorable Risk Factors following Brachytherapy (2010) (1)
- Pre-biopsy Prostate-specific Antigen Velocity does not Predict Gleason Score, Tumor Location or Cancer Volume Following Transperineal-template Guided Prostate Mapping Biopsy: Implications for Prostate Brachytherapy Treatment Planning (2008) (1)
- The Role of Trospium Chloride in Brachytherapy-Related Detrusor Overactivity (2007) (0)
- Serum Testosterone Changes in Patients with a PSA Spike Following Prostate Brachytherapy (2010) (0)
- Prostate volume changes contribute to increase in rectal dose between day 0 and day 30 following permanent prostate brachytherapy (2008) (0)
- Malpractice in radiation oncology: redefining the role of the medical expert: in regard to Kagan (Int J Radiat Oncol Biol Phys 2005;61:638-639). (2005) (0)
- Single Fraction Radiotherapy as Postoperative Treatment (SF-PORT) for Resected, Stage I/II Merkel Cell Carcinoma. (2021) (0)
- Extracapsular radiation dose annulus correlates with biochemical control in low-risk brachytherapy patients: Results of a prospective randomized trial (2006) (0)
- Rebuttal to Drs. Shteynshlyuger and Kibel (2010) (0)
- 2311 : Serial Ultrasound-Determined Post-Void Residual Urine Volumes During External Beam Radiation Therapy for Clinically Localized Prostate Cancer (2006) (0)
- 2274 : The Impact of Body Mass Index on Cause-Specific Biochemical and Overall Survival Following Permanent Prostate Brachytherapy (2006) (0)
- Hyperthermic Potentiation of m-Diamminedichloroplatinum ( II ) Cytotoxicity in Chinese Hamster Ovary Cells Resistant to the Drug 1 (2006) (0)
- 416C Brachytherapy for early prostate cancer — part II: Treatment, results, side effects and complications (1997) (0)
- Interstitial implant alone with or without external beam radiation therapy for intermediate risk localized prostate cancer: Patterns of Care Study in the United States (2006) (0)
- IODINE-125 IMPLANTS FOR PROSTATE CANCER. AUTHOR'S REPLY (1992) (0)
- 180 Treatment margins for prostate brachytherapy (2000) (0)
- Transperineal Template-Guided Mapping Biopsy as a Staging Procedure to Select Patients Best Suited for Active Surveillance: Implications for Treatment Planning (2011) (0)
- 7 Prostate cancer treatment costs (2000) (0)
- Morbidity of permanent I-126 transperineal prostate implantation (1993) (0)
- Long-term Rectal Function After Permanent Interstitial Prostate Brachytherapy (2011) (0)
- Morbidity after brachytherapy for prostate adenocarcinoma. Authors' replies (2004) (0)
- Conundrums of coronary brachytherapy. (2022) (0)
- In reply to Dr. Lee (2004) (0)
- Prognostic Significance of Perineural Invasion on Biochemical Progression-Free Survival Following Prostate Brachytherapy (2005) (0)
- SU‐FF‐T‐73: An Intra‐Operative Dosimetry System for Prostate Brachytherapy Using Dual‐Modality Imaging (2007) (0)
- Biochemical and functional outcomes following brachytherapy in men ≤ 50 years of age with clinically localized prostate cancer (2008) (0)
- Adolescent Awareness of Testicular Self Examination and Testicular Cancer (2009) (0)
- Temporal relationship between colorectal cancer and clinically localized prostate cancer in patients managed with permanent interstitial brachytherapy (2006) (0)
- SU‐FF‐T‐239: Extracapsular Radiation Dose Annulus Correlates with Biochemical Control in Low‐Risk Brachytherapy Patients: Results of a Prospective Randomized Trial (2006) (0)
- Higher percentage of positive biopsy cores and Gleason score are associated with a greater degree of prostate gland shrinkage after neoadjuvant cytoreductive therapy. (2012) (0)
- The role of trospium chloride in brachytherapy-related urinary morbidity (2007) (0)
- Effect of obesity on overall survival following permanent prostate brachytherapy (2007) (0)
- Urinary morbidity following transperineal template-guided prostate saturation biopsy (2007) (0)
- 239 A NOVEL PIG MODEL OF CYSTIC FIBROSIS GENERATED BY SEQUENTIAL TARGETING OF CFTR BY BACTERIAL ARTIFICIAL CHROMSOME VECTORS (2012) (0)
- Relationship between Prebrachytherapy Erectile Function, Age and Overall Survival (2010) (0)
- Comparison of Annular Treatment Margins and Sector Analysis between Biochemical Failures and Matched Non-failures in Brachytherapy Patients with High Quality Intraprostatic Dosimetry (2010) (0)
- Prediction of PSA spikes by isotope and patient age following permanent prostate brachytherapy (2007) (0)
- 20 Gy vs. 44 Gy of Supplemental External Beam Radiation with PD-103 Brachytherapy for Patients with Higher Risk Disease: Results of a Prospective Randomized Trial (2011) (0)
- Distribution of Cancer Foci Identified with Transperineal Template-guided Biopsies: Implications for Focal and Other Prostate Cancer Definitive Treatment (2009) (0)
- CT Patterns of Recurrent Malignant Astrocytoma (1989) (0)
- Pre-treatment Prostate Cancer Volume and Biopsy Gleason Score Predicts Prostate Gland and Transition Zone Shrinkage following Neoadjuvant Cytoreductive Therapy (2010) (0)
- Obesity Does Not Correlate with Adverse Pathologic Findings on Transperineal Template-guided Mapping Biopsy of the Prostate (2009) (0)
- Influence of Preimplant International Prostate Symptom Score on Urinary Morbidity Following Prostate Brachytherapy (2005) (0)
- Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity (2005) (0)
- Point: Prostate carcinoma treatment for the young patient--the case for brachytherapy. (2010) (0)
- Serum Testosterone Kinetics following Brachytherapy for Clinically Localized Prostate Cancer (2010) (0)
- In response to Dr. Rubenstein (2005) (0)
- Prostate brachytherapy in men greater than or equal to 75 years of age (2008) (0)
- Erectile Function After Prostate Brachytherapy (2006) (0)
- 113 Brachytherapy for prostate cancer (1995) (0)
- The role of androgen deprivation therapy in high-risk prostate cancer with Gleason score 8-10 and prostate-specific antigen ≤15 treated with permanent interstitial brachytherapy (2009) (0)
- Abstract2287: The Impact of Primary Gleason Pattern on Survival Following Brachytherapy for Gleason Score 7 Prostate Cancer (2006) (0)
- Nursing considerations in brachytherapy-related erectile dysfunction. (2005) (0)
- Prostate brachytherapy dosimetry with dual modality imaging (2002) (0)
- Commentary on "Medical malpractice in the age of technology: how specialty societies can make a difference (Anscher and Anscher)". (2006) (0)
- (Potential) mishaps of high dose rate vaginal cuff brachytherapy. (2023) (0)
- Treating Prostate Cancer (2008) (0)
- Pre-biopsy prostate-specific antigen velocity does not predict Gleason score, tumor location or cancer volume following transperineal template-guided prostate mapping biopsy (2008) (0)
- Permanent prostate brachytherapy in prostate glands less than 20 cm3 (2009) (0)
- Differences in prostate volume delineation on post-prostate brachytherapy CT scans among experienced brachytherapists and their effect on dosimetric parameters (2002) (0)
- Efficacy of Neoadjuvant Dutasteride and Bicalutamide as a Cytoreductive Regimen Prior to Permanent Interstitial Brachytherapy (2005) (0)
- SU‐FF‐T‐55: Variability of Prostate Brachytherapy Preimplant Dosimetry: A Multi‐Institutional Analysis (2005) (0)
- IN REGARDS TO WALLNER ET AL: 125 I VERSUS 103 PD FOR LOW-RISK PROSTATE CANCER: PRELIMINARY PSA (2004) (0)
- I-125 Versus Pd-103 for Low Risk Prostate Cancer: Morbidity Outcomes From a Prospective Randomized Multi-center Controlled Trial (2005) (0)
- SU‐FF‐T‐131: Cs‐131 Prostate Brachytherapy and Treatment Plan Parameters (2007) (0)
- In response to Drs. Pollack and Horwitz (2002) (0)
- Commentary (Wallner): Locoregional Therapies for Early-Stage Prostate Cancer (1995) (0)
- Androgen-deprivation Therapy— A Help or a Hindrance for Survival in High-risk Prostate Cancer? (2008) (0)
- The meaning of prescription dose and D90 in permanent seed prostate brachytherapy (2006) (0)
- High quality brachytherapy dose distributions obviate the need for high dose supplemental external beam radiation in patients with higher risk features: Results of a prospective randomized trial (2008) (0)
- The impact of primary Gleason pattern on survival following brachytherapy for Gleason 7 prostate cancer (2007) (0)
- Electromagnetic Transponders Indicate Size Fluctuation during the Course of External Beam Radiation Therapy (2009) (0)
- In regard to Ghaly. Authors' reply (2003) (0)
- Factors predicting prostate gland shrinkage following neoadjuvant cytoreductive therapy (2009) (0)
- The prognostic value of percent positive biopsies in intermediate to high risk prostate cancer treated with brachytherapy and supplemental beam radiotherapy. (2006) (0)
- 20 Gy Versus 44 Gy Supplemental Beam Radiation With Pd-103 Prostate Brachytherapy: Preliminary Biochemical Outcomes From a Prospective Randomized Multi-Center Trial (2006) (0)
- 2291 : Is D90 a Radiobiologically Sound Endpoint for Evaluation Permanent Seed Prostate Brachytherapy? (2006) (0)
- Prostate Brachytherapy-Induced Urethral Strictures (2005) (0)
- The impact of primary Gleason pattern on survival following brachytherapy for Gleason score 7 prostate cancer (2007) (0)
- Comparison o f t he 5 -Year O utcome a nd M orbidity of T hree-Dimensiona l C onformal R adiotherapy Versus T ransperineal P ermanent I odine-125 I mplantation for E arly-Stage P rostatic C ancer (1999) (0)
- Registration of prostate brachytherapy seeds with prostate anatomy for improved patient dosimetry (2002) (0)
- 125I in prostate cancer (1992) (0)
- Matching protocol and practice:The challenge of meeting lung and kidney total body irradiation constraints for scleroderma. (2023) (0)
- The impact of pretreatment serum testosterone on survival following permanent prostate brachytherapy (2008) (0)
- Long-Term Outcome for Very High Risk Prostate Cancer Treated With Permanent Interstitial Brachytherapy (2011) (0)
- Medical malpractice and brachytherapy. (2020) (0)
- The Role of Androgen Deprivation Therapy in High Risk Prostate Cancer with Gleason Score 8-10 and PSA ≤ 15 Ng/Ml Treated with Permanent Interstitial Brachytherapy (2009) (0)
- Severe rectal complications after prostate brachytherapy q (2015) (0)
- The Influence of External Beam Radiation Therapy on Ultrasound Determined Post Void Residual Urine Volumes for Clinically Localized Prostate Cancer (2008) (0)
- 2228 : Long-Term Rectal Function Following Permanent Prostate Brachytherapy (2006) (0)
- In regards to wallner Et al: 125I versus 103PD for low-risk prostate cancer: Preliminary psa outcomes from a prospective randomized multicentertrial. Authors' reply (2004) (0)
- Iodine-125 implants for prostate cancer. (1992) (0)
- Prostate brachytherapy as monotherapy: Are there gaps, holes, and islands in the argument? Authors' reply (2005) (0)
- Global Oncology in the United States: Radiation Therapy for the Homeless in King County, Washington (2020) (0)
- Biochemical and Functional Outcomes Following Brachytherapy in Men Less than or Equal to 50 Years of Age with Clinically Organ-confined Prostate Cancer (2008) (0)
- 338 BACTERIAL ARTIFICIAL CHROMOSOME (BAC) VECTORS FACILITATE EFFICIENT GENE TARGETTING IN KIDNEY CELLS OF PIG (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Kent E. Wallner?
Kent E. Wallner is affiliated with the following schools:
